Springer Book Archives: eBooks only 8.99 each! Save now >>

Milestones in Drug Therapy

ACE Inhibitors

Editors: D'Orléans-Juste, Pedro, Plante, G.E. (Eds.)

Free Preview

Buy this book

eBook $74.99
price for USA in USD (gross)
  • ISBN 978-3-0348-7579-0
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Softcover $99.00
price for USA in USD
  • ISBN 978-3-0348-7581-3
  • Free shipping for individuals worldwide
  • Immediate ebook access, if available*, with your print order
  • Usually dispatched within 3 to 5 business days.
About this book

Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis­ order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun­ tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop­ ment almost failed when serious side-effects were reported in an alarmist fash­ ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar­ macological actions.

Table of contents (14 chapters)

Table of contents (14 chapters)
  • The history of inhibitors of angiotensin converting enzyme

    Pages 1-10

    Vane, John R.

  • Genetics of the renin-angiotensin-aldosterone system and risk of arterial disease

    Pages 11-27

    Lajemi, Malika (et al.)

  • Crosstalk between ACE inhibitors, B2 kinin receptor and nitric oxide in endothelial cells

    Pages 29-36

    Wohlfart, Paulus (et al.)

  • Interactions between the ACE and the endothelin pathway

    Pages 37-45

    Hopfner, Rob L. (et al.)

  • Evaluative and epidemiological approaches of ACE therapy

    Pages 47-70

    Lamarre-Cliche, Maxime (et al.)

Buy this book

eBook $74.99
price for USA in USD (gross)
  • ISBN 978-3-0348-7579-0
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Softcover $99.00
price for USA in USD
  • ISBN 978-3-0348-7581-3
  • Free shipping for individuals worldwide
  • Immediate ebook access, if available*, with your print order
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
ACE Inhibitors
Editors
  • Pedro D'Orléans-Juste
  • G.E. Plante
Series Title
Milestones in Drug Therapy
Copyright
2001
Publisher
Birkhäuser Basel
Copyright Holder
Springer Basel AG
eBook ISBN
978-3-0348-7579-0
DOI
10.1007/978-3-0348-7579-0
Softcover ISBN
978-3-0348-7581-3
Series ISSN
2296-6056
Edition Number
1
Number of Pages
X, 187
Number of Illustrations
24 b/w illustrations
Topics

*immediately available upon purchase as print book shipments may be delayed due to the COVID-19 crisis. ebook access is temporary and does not include ownership of the ebook. Only valid for books with an ebook version. Springer Reference Works are not included.